Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 10,785 Shares

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 10,785 shares of the firm’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $55.07, for a total value of $593,929.95. Following the sale, the insider owned 282,008 shares in the company, valued at $15,530,180.56. This trade represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The shares were sold at an average price of $39.80, for a total value of $203,378.00.
• On Wednesday, September 3rd, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $37.87, for a total value of $103,195.75.

Apogee Therapeutics Price Performance

NASDAQ:APGE traded down $0.28 during mid-day trading on Friday, reaching $54.71. The company’s stock had a trading volume of 523,026 shares, compared to its average volume of 808,892. The stock has a market cap of $2.52 billion, a P/E ratio of -13.25 and a beta of 1.50. The company’s fifty day simple moving average is $45.64 and its two-hundred day simple moving average is $41.37. Apogee Therapeutics Inc. has a twelve month low of $26.20 and a twelve month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.10). Sell-side analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Institutional Trading of Apogee Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Apogee Therapeutics during the second quarter worth about $218,000. Bank of New York Mellon Corp grew its stake in Apogee Therapeutics by 93.3% during the 1st quarter. Bank of New York Mellon Corp now owns 214,231 shares of the company’s stock valued at $8,004,000 after purchasing an additional 103,404 shares in the last quarter. Victory Capital Management Inc. grew its stake in Apogee Therapeutics by 4.4% during the 1st quarter. Victory Capital Management Inc. now owns 232,983 shares of the company’s stock valued at $8,704,000 after purchasing an additional 9,921 shares in the last quarter. Woodline Partners LP increased its holdings in Apogee Therapeutics by 4.5% during the 1st quarter. Woodline Partners LP now owns 1,061,053 shares of the company’s stock worth $39,641,000 after purchasing an additional 45,445 shares during the last quarter. Finally, AlphaQuest LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at approximately $43,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

APGE has been the topic of a number of research analyst reports. BTIG Research reiterated a “buy” rating and issued a $115.00 price target on shares of Apogee Therapeutics in a report on Thursday, October 9th. Bank of America lifted their target price on Apogee Therapeutics from $78.00 to $87.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Wedbush reissued an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $96.50.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.